TORONTO & AUSTIN, Texas--(BUSINESS WIRE)--Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced that it will present at the 25th BioCentury Future Leaders conference at the Millennium Broadway Hotel & Conference Center in New York City. Chief Executive Officer and President, Paul Lammers, M.D., M.Sc. will be presenting on March 23 from 8:45-9:00am ET in Presentation Room 508.
Dr. Lammers will provide an overview of Triumvira and the improvements the company is making over current therapies with its novel immuno-oncology platform T Cell-Antigen Coupler (TAC). Dr. Lammers will also be giving updates on Triumvira’s lead drug, CD19 TAC#921, which is targeted to enter clinical development in Q1 2019 – Phase 1/2 in patients with relapsing/refractory diffuse large B-cell lymphoma (DLBCL).
The Future Leaders conference offers Wall Street and pharma executives the opportunity to assess private and public companies with healthy financial profiles, poised to deliver on milestones that could lead to the next tier of valuations.
About Triumvira Immunologics
Triumvira Immunologics is an immuno-oncology company, developing a novel platform for engineering T cells to attack both liquid and solid cancers. Triumvira’s proprietary T Cell-Antigen Coupler (TAC) co-opts the natural T Cell receptor biology and functions. Since the proprietary technology operates through the native T cell receptor, as opposed to a more synthetic design that can result in toxicities, TAC receptors possess advantages over other approaches. Triumvira’s pipeline includes multiple trials which are clinic-ready in 2019.